Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Oct 24;27(21):7187.
doi: 10.3390/molecules27217187.

Sources, Transformations, Syntheses, and Bioactivities of Monoterpene Pyridine Alkaloids and Cyclopenta[c]pyridine Derivatives

Affiliations
Review

Sources, Transformations, Syntheses, and Bioactivities of Monoterpene Pyridine Alkaloids and Cyclopenta[c]pyridine Derivatives

Xuejian Zhang et al. Molecules. .

Abstract

Monoterpene pyridine alkaloids (MTPAs) are alkaloids derived from iridoid glycosides (IGs). The common molecular structure of MTPAs is the pyridine ring, while some of them have a cyclopenta[c]pyridine skeleton. Some compounds containing this structure are potentially bioactive medicinal agents. In this paper, seven drug candidates (A-G), ninety natural source products (1-90), thirty-seven synthesized compounds (91-127), as well as twenty-six key intermediates (S1-S26) were summarized. We categorized five types of MTPAs and one type of cyclopenta[c]pyridine alkaloids in all. Additionally, their possible genetic pathways were proposed. Then, the chemical transformation, biotransformation, chemical synthesis, as well as the bioactivity of MTPAs and cyclopenta[c]pyridine derivatives were analyzed and summarized. Cyclopenta[c]pyridine derivatives can be concisely and chirally synthesized, and they have shown potentials with antibacterial, insecticidal, antiviral, anti-inflammatory, and neuropharmacological activities.

Keywords: bioactivity; cyclopenta[c]pyridine derivatives; monoterpene pyridine alkaloids; source; synthesis; transformation.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 2
Figure 2
Structures of pyridine alkaloids derived from 4-demethyliridoids (Type I).
Figure 3
Figure 3
Structures of pyridine alkaloids derived from iridoids (Type II).
Figure 4
Figure 4
Pyridine alkaloids derived from hemiacetal secoiridoid (Type III).
Figure 5
Figure 5
Structures of pyridine alkaloids derived from secoiridoids (Type IV).
Figure 6
Figure 6
Structures of pyridines alkaloids derived from lactone secoiridoids (Type V).
Figure 7
Figure 7
Structures of phenyl-substituted cyclopenta[c]pyridine derivatives (Type VI).
Figure 1
Figure 1
Examples of bioactive cyclopenta[c]pyridine derivatives.
Scheme 1
Scheme 1
Possible genetic pathways from iridoids to MTPAs.
Scheme 2
Scheme 2
Possible ammonization and aromatization pathway from iridoids to MTPAs.
Scheme 3
Scheme 3
Proposed genetic pathway for (±)-27 and (±)-28.
Scheme 4
Scheme 4
Amination of secoiridoid glycosides ((A), oleuropein and ligstroside as substrates; (B), methyloleoside as substrates) to give monomeric pyridine, dimeric pyridine, and naphthyridine alkaloids.
Scheme 5
Scheme 5
MTPAs produced from IGs.
Scheme 6
Scheme 6
Possible transformation mode to afford a monomeric MTPA (88) and the dimeric MTPA (40).
Scheme 7
Scheme 7
Possible biosynthetic route of compound 89.
Scheme 8
Scheme 8
Compound 57 yielded from Aspergillus niger (A) or Cordyceps sinensis (B) by means of biotransformation.
Scheme 9
Scheme 9
Conversion of three harpagide congeners to aucubinine B (5) by β-glucosidase in the presence of NH4OAc or by human intestinal flora (A); possible metabolic processes of aucubin by human intestinal bacteria (B).
Scheme 10
Scheme 10
One-step synthesis of the monoterpene natural product, (−)-actinidine (29).
Figure 8
Figure 8
Cyclopenta[c]pyridine products (91112) obtained from a concise biomimic access.
Scheme 11
Scheme 11
(A), Synthesis of cyclopenta[c]pyridine from genipin; (B), possible reaction mechanism.
Scheme 12
Scheme 12
Reactions afforded cyclopenta[c]pyridine derivatives.
Scheme 13
Scheme 13
The Kondrat’eva Reaction in Flow: synthesis of annulated pyridines.
Scheme 14
Scheme 14
Diastereoselective synthesis of actinidine (4).
Scheme 15
Scheme 15
Total synthesis of the monoterpene alkaloids (−)-plectrodorine (127) and (+)-oxerine (20).

Similar articles

Cited by

References

    1. Vitaku E., Smith D.T., Njardarson J.T. Analysis of the structural diversity, substitution patterns, and frequency of nitrogen heterocycles among USA FDA approved pharmaceuticals. J. Med. Chem. 2014;57:10257–10274. doi: 10.1021/jm501100b. - DOI - PubMed
    1. Li L., Zou J.-Y., You S., Deng Z., Liu Y., Wang Q. Natural product cerbinal and its analogues cyclopenta [c] pyridines: Synthesis and discovery as novel pest control agents. J. Agric. Food Chem. 2019;67:10498–10504. doi: 10.1021/acs.jafc.9b03699. - DOI - PubMed
    1. Dyachenko I.V., Dyachenko V.D. Cycloalka [c] pyridine derivatives. Methods of synthesis and chemical properties. Russ. J. Org. Chem. 2017;53:1769–1787. doi: 10.1134/S1070428017120016. - DOI
    1. Martin R.E., Lehmann J., Alzieu T., Lenz M., Corrales M.A.C., Aebi J.D., Märki H.P., Kuhn B., Amrein K., Mayweg A.V., et al. Synthesis of annulated pyridines as inhibitors of aldosterone synthase (CYP11B2) Org. Biomol. Chem. 2016;14:5922–5927. doi: 10.1039/C6OB00848H. - DOI - PubMed
    1. Lehmann J., Alzieu T., Martin R.E., Britton R. The Kondrat’eva reaction in flow: Direct access to annulated pyridines. Org. Lett. 2013;15:3550–3553. doi: 10.1021/ol4013525. - DOI - PubMed

LinkOut - more resources